BioInvent International AB - Product Pipeline Review - 2014

Published: Apr, 2014 | Pages: 34 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

BioInvent International AB - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'BioInvent International AB - Product Pipeline Review - 2014', provides an overview of the BioInvent International AB's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of BioInvent International AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of BioInvent International AB including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of BioInvent International AB's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the BioInvent International AB's pipeline products

Reasons to buy

- Evaluate BioInvent International AB's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of BioInvent International AB in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the BioInvent International AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of BioInvent International AB and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of BioInvent International AB
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of BioInvent International AB and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
BioInvent International AB Snapshot 5
BioInvent International AB Overview 5
Key Information 5
Key Facts 5
BioInvent International AB - Research and Development Overview 6
Key Therapeutic Areas 6
BioInvent International AB - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
BioInvent International AB - Pipeline Products Glance 14
BioInvent International AB - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
BioInvent International AB - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
BioInvent International AB - Drug Profiles 17
BI-505 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
BI-1206 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Monoclonal Antibody for Inflammation 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Antibodies Against Tumour-Associated Macrophages 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Antibody Program For Blood Cancers 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
BioInvent International AB - Pipeline Analysis 22
BioInvent International AB - Pipeline Products by Target 22
BioInvent International AB - Pipeline Products by Route of Administration 23
BioInvent International AB - Pipeline Products by Molecule Type 24
BioInvent International AB - Pipeline Products by Mechanism of Action 25
BioInvent International AB - Recent Pipeline Updates 26
BioInvent International AB - Discontinued Pipeline Products 28
Discontinued Pipeline Product Profiles 28
BI-201 28
BI-204 28
BioInvent International AB - Company Statement 29
BioInvent International AB - Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34

List of Tables
BioInvent International AB, Key Information 5
BioInvent International AB, Key Facts 5
BioInvent International AB - Pipeline by Indication, 2014 7
BioInvent International AB - Pipeline by Stage of Development, 2014 8
BioInvent International AB - Monotherapy Products in Pipeline, 2014 9
BioInvent International AB - Partnered Products in Pipeline, 2014 10
BioInvent International AB - Partnered Products/ Combination Treatment Modalities, 2014 11
BioInvent International AB - Out-Licensed Products in Pipeline, 2014 12
BioInvent International AB - Out-Licensed Products/ Combination Treatment Modalities, 2014 13
BioInvent International AB - Phase II, 2014 14
BioInvent International AB - Preclinical, 2014 15
BioInvent International AB - Discovery, 2014 16
BioInvent International AB - Pipeline by Target, 2014 22
BioInvent International AB - Pipeline by Route of Administration, 2014 23
BioInvent International AB - Pipeline by Molecule Type, 2014 24
BioInvent International AB - Pipeline Products by Mechanism of Action, 2014 25
BioInvent International AB - Recent Pipeline Updates, 2014 26
BioInvent International AB - Discontinued Pipeline Products, 2014 28
BioInvent International AB, Subsidiaries 32